14β-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity

Journal of Medicinal Chemistry

Volumn 52, Issue 6, 2009, Pages 1553-1557

  Moynihan, H ^a   Jales, A R ^a   Greedy, B M ^b   Rennison, D ^b   Broadbear, J H ^c   Purington, L ^c   Traynor, J R ^c   Woods, J H ^c   Lewis, J W ^b   Husbands, S M ^a,b  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 CINNAMOYLAMINOMORPHINONE DERIVATIVE; 14BETA O CINNAMOYLNATREXONE; CINNAMOYLOXYCODEINONE DERIVATIVE; CINNAMOYLOXYMORPHINONE DERIVATIVE; HYDROCODONE DERIVATIVE; MORPHINE; MORPHINONE; MU OPIATE RECEPTOR; NALTREXONE; NALTRINDOLE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; NONHUMAN;

HYDROCODONE; MAGNETIC RESONANCE SPECTROSCOPY; NALTREXONE; RECEPTORS, OPIOID, MU; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 64349089490     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8012272     Document Type: Article

References (19)

1. Kreek, M. J. In Handbook of Experimental Pharmacology; Schuster. C. R., Kuhar, M. J., Eds.; Springer: Berlin, 1996; Vol. 118, p 563.
2. Pettinati, H. M.; O'Brien, C. P.; Rabinowitz, A. R.; Wortman, S. P.; Oslin, D. W.; Kampman, K. M.; Dackis, C. A. The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. J. Clin. Psychopharmacol. 2006, 26, 610-625.
3. Sporer, K. A. Acute heroin overdose. Ann. Intern. Med. 1999, 130, 84-90.
4. Kobylecki, R. J.; Carling, R. W.; Lord, J. A. H.; Smith, C. F. C.; Lane, A. C. Common anionic receptor site hypothesis: Its relevance to the antagonist action of naloxone. J. Med. Chem. 1982, 25, 116-120.
5. Schullner, F.; Meditz, R.; Krassnig, R.; Morandell, G.; Kalinin, V. N.; Sandler, E.; Spetea, M.; White, A.; Schmidhammer, H.; Berzetei- Gurske, I. Synthesis and biological evaluation of 14-alkoxymorphinans. 19. Effect of 14-O-benzylation on the opioid receptor affinity and antagonist potency of naltrexone. Helv. Chim. Acta 2003, 86, 2335-2341.
6. Greiner, E.; Spetea, M.; Krassnig, R.; Schuller, F.; Aceto, M. D.; Harris, L. S.; Traynor, J. R.; Woods, J. H.; Coop, A.; Schmidhammer, H. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-Substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: Extending the scope of common structure- activity relationships. J. Med. Chem. 2003, 46, 1758-1763.
7. Aceto, M. D.; Bowmen, E. R.; May, E. L.; Woods, J. H.; Smith, C. B.; Medzihradsky, F.; Jacobson, A. E. Very long-acting narcotic antagonists: The 14β-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives. Arzneim. Forsch. 1989, 39, 570-575.
8. Broadbear, J. H.; Sumpter, T. L.; Burke, T. F.; Husbands, S. M.; Lewis, J. W.; Woods, J. H.; Traynor, J. R. Methcinnamox is a potent, long- lasting and selective antagonist of morphine-mediated antinociception in the mouse: Comparison with clocinnamox, β-FNA and β-chlorn-altrexamine. J. Pharmacol. Exp. Ther. 2000, 294, 933-940.
9. Nieland, N. P. R.; Moynihan, H.; Carrington, S.; Broadbear, J.; Woods, J. H.; Traynor, J. R.; Husbands, S. M.; Lewis, J. W. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: Effect of substitution in the aromatic ring of cinnamoylaminomor-phinones and codeinones. J. Med. Chem. 2006, 49, 5333-5338.
10. Rennison, D.; Moynihan, H.; Traynor, J. R.; Lewis, J. W.; Husbands, S. M. Structural determinants of opioid activity in derivatives of 14- aminomorphinones: Effects of changes to the C14-amino to aryl ring linker chain. J. Med. Chem. 2006, 49, 6104-6110.
11. Armesto, N.; Ferrero, M.; Fernandez, S.; Gotor, V. Novel enzymatic synthesis of 4-o-cinnamoyl quinic and shikimic acid derivatives. J. Org. Chem. 2003, 68, 5784-5787.
12. 6 bond in dihydromorphinone and related opiates. J. Org. Chem. 1989, 54, 4120-U25.
13. Toll, L.; Berzetei-Gurske, I. P.; Polgar, W. E.; Brandt, S. R.; Adapa, I. D.; Rodriguez, L.; Schwartz, R. W.; Haggart, D.; O'Brian, A.; White, A.; Kennedy, J. M.; Craymer, K.; Farrington, L.; Auh, J. S. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monogr. 1998, 178, 440-466.
14. Zaveri, N.; Polgar, W. E.; Olsen, C. M.; Kelson, A. B.; Grundt, P.; Lewis, J. W.; Toll, L. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur. J. Pharmacol. 2001, 428, 29-36.
15. Hambrook, J. M.; Rance, M. J. The interaction of buprenorphine with the opiate receptor. In Opiates and Endogenous Opioid Peptides; Kosterlitz, H. W., Ed.; Elsevier: Amsterdam, 1976; pp 295-301.
16. Zernig, G.; Butelman, E. R.; Lewis, J. W.; Walker, E. A.; Woods, J. H. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J. Pharmacol. Exp. Ther. 1994, 269, 57-65.
17. Sebastian, A.; Bidlack, J. M.; Jiang, Q.; Deecher, D.; Teitler, M.; Glick, S. D.; Archer, S. 14β-[(p-Nitrocinnamoyl)amino]morphinones, 14β- [p-nitrocinnamoyl)amino]-7,8-dihydromorphinones and their codeino-ne analogues: Synthesis and receptor activity. J. Med. Chem. 1993, 36, 3154-3160.
18. Husbands, S. M.; Lewis, J. W. Opioid ligands having delayed long-term antagonist activity: Potential pharmacotherapies for opioid abuse. Mini-Rev. Med. Chem. 2003, 3, 137-144.
19. Spagnolo, B.; Calo, G.; Polgar, W. E.; Jiang, F.; Olsen, C. M.; Berzatei-Gurske, I.; Khroyan, T. V.; Husbands, S. M.; Lewis, J. W.; Toll, L.; Zaveri, N. T. Activities of mixed NOP and μ-opioid receptor ligands. Br. J. Pharmacol. 2008, 153, 609-619.